Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

Antimicrobial Agents and Chemotherapy
G W KaatzM J Rybak

Abstract

Trovafloxacin is a new fluoronaphthyridone chemically and functionally related to members of the fluoroquinolone class of antimicrobial agents. The in vivo efficacy of the drug was compared with that of vancomycin by using the rabbit model of left-sided endocarditis. Rabbits infected with either a nafcillin-susceptible or -resistant test strain were treated with trovafloxacin (13.3 mg/kg of body weight every 12 h) or vancomycin (25 mg/kg of body weight every 8 h) for 4 days. In comparison with untreated controls, both antimicrobial agents effectively cleared bacteremia and significantly reduced bacterial counts in vegetations and tissues of animals infected with either test strain. No resistance to trovafloxacin emerged in test strains during therapy. We conclude that in this model trovafloxacin is as efficacious as vancomycin is and may serve as a viable alternative to vancomycin for use in humans with similar infections.

References

Feb 1, 1990·Antimicrobial Agents and Chemotherapy·G W KaatzM J Rybak
Apr 1, 1989·Antimicrobial Agents and Chemotherapy·G W KaatzM J Rybak
Apr 1, 1970·Applied Microbiology·H J Simon, E J Yin
Jan 1, 1983·Therapeutic Drug Monitoring·K S SchwenzerJ P Anhalt
Nov 1, 1994·Antimicrobial Agents and Chemotherapy·H C Neu, N X Chin
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·G M EliopoulosR C Moellering
May 1, 1996·The Journal of Antimicrobial Chemotherapy·R TengS C Harris
Aug 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L Verbist, J Verhaegen
Sep 1, 1996·Diagnostic Microbiology and Infectious Disease·H F BonillaC A Kauffman
Jun 1, 1997·The Journal of Antimicrobial Chemotherapy·K E Brighty, T D Gootz
Jun 1, 1997·The Journal of Antimicrobial Chemotherapy·A M SeftonJ D Williams

❮ Previous
Next ❯

Citations

Aug 25, 1999·The Journal of Antimicrobial Chemotherapy·B AmorenaJ Hernández-Yago
Dec 31, 1998·Antimicrobial Agents and Chemotherapy·J M EntenzaP Moreillon
Feb 11, 1999·The Annals of Pharmacotherapy·A A Alghasham, M C Nahata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.